Strategies to tackle RAS-mutated metastatic colorectal cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• RAS oncogenes are frequently mutated in metastatic colorectal cancer (mCRC), leading to poor prognosis and resistance to anti-EGFR therapies.
• Historically, targeting RAS mutations has been challenging, with RAS often deemed 'undruggable'.

Purpose of the Study:

• To review current and emerging strategies for targeting RAS mutations in mCRC.
• To evaluate the efficacy and potential of novel RAS-targeting approaches.

Main Methods:

• Literature review of clinical and preclinical data on RAS-targeting strategies in mCRC.
• Analysis of five main therapeutic approaches: direct RAS targeting, MAPK pathway inhibition, immunotherapy combinations, metabolic pathway targeting, and miscellaneous methods.

Main Results:

• Direct KRAS^G12C inhibition shows promise in mCRC but has limitations in response duration.
• Combinational therapies (e.g., with anti-EGFR drugs or checkpoint inhibitors) and metabolic stress-inducing therapies are under investigation to enhance efficacy.
• Emerging strategies offer new hope for treating mCRC with RAS mutations.

Conclusions:

• RAS mutations are increasingly targetable, moving beyond the 'undruggable' paradigm.
• Future clinical translation of novel RAS-targeting therapies in mCRC is anticipated.
• Combinatorial approaches are key to overcoming current treatment limitations.